Area of research
Cardiology and Cardiovascular Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Chemotherapy-induced cardiotoxicity and mitigation, Cardiac Imaging and Diagnostics, Cardiac Valve Diseases and Treatments, and Cardiovascular Function and Risk Factors.
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia.
Obituary: Jesús Saldaña García
Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy During Active Chemotherapy
Contemporary management of atrial fibrillation in patients with cancer-the 2025 European Heart Rhythm Association survey.
Immune checkpoint inhibitor-associated myocarditis: a novel risk score
Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis
Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
Cardiovascular Safety in Oncology Clinical Trials
Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council Perspective.
An update on the European Society of Cardiology Council of Cardio-Oncology.
Advances in Cardioprotection Strategies: Focusing on Breast Cancer and Beyond Through Novel Biomarkers and Pharmacological Approaches
The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology.
GLP1 agonists in cardio-oncology: is it time for a specific focus?
Development of three-step holistic care pathways to detect and manage comorbidities in patients with atrial fibrillation: the Horizon 2020 EHRA-PATHS consortium.
A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging.
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
Cardiovascular Considerations Before Cancer Therapy
Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and <i>JACC: CardioOncology</i> Expert Panel Recommendations.
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes
Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score
SGLT2i and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction in Patients With Diabetes.
Cardio-oncology: chances and challenges
Ischaemic heart disease in patients with cancer.
Breast cancer and cardiovascular health.
Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis
The BALTO Registry: Long‐term results of percutaneous BALloon pericardioTomy in oncological patients
Education in cardio-oncology: the next frontiers.
Letter by Cardinale et al Regarding Article, "Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial".